..tpm diclo launch in the new year!
Themis Medicare, which is a partner firm of Australian drug delivery technology company Phosphagenics, entered into a license and supply agreement with Novartis India to sell its Themis diclofenac topical gel formulated using a unique TPM transdermal drug delivery system. The drug delivery system is available only with Themis in India. The information was revealed by Themis Medicare in a release to the Bombay Stock Exchange (BSE) post market on Friday, April 12, 2013.
Phosphagenics welcomed the exciting commercial expansion and said that endorsement by Novartis India is a significant validation its TPM technology by a global pharmaceutical company. - See more at: http://www.biospectrumasia.com/biospectrum/news/187024/novartis-sell-themis-diclofenac-topical-gel#.UmxEW-q4Yps
novartis and poh ease the pain
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.366K | 455.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 99145902 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 22467224 | 7 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |